Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $5.9 million.

  • Gyre Therapeutics' Profit After Tax rose 10784.31% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 11412.47%. This contributed to the annual value of $17.9 million for FY2024, which is 12093.82% up from last year.
  • As of Q3 2025, Gyre Therapeutics' Profit After Tax stood at $5.9 million, which was up 10784.31% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Profit After Tax peaked at $51.6 million during Q2 2022, and registered a low of -$101.0 million during Q4 2023.
  • In the last 5 years, Gyre Therapeutics' Profit After Tax had a median value of $1.6 million in 2025 and averaged -$7.4 million.
  • Per our database at Business Quant, Gyre Therapeutics' Profit After Tax tumbled by 45361.46% in 2021 and then skyrocketed by 35909.27% in 2022.
  • Quarter analysis of 5 years shows Gyre Therapeutics' Profit After Tax stood at -$20.3 million in 2021, then plummeted by 37.23% to -$27.9 million in 2022, then crashed by 261.95% to -$101.0 million in 2023, then soared by 100.56% to $569000.0 in 2024, then soared by 943.23% to $5.9 million in 2025.
  • Its Profit After Tax stands at $5.9 million for Q3 2025, versus $1.6 million for Q2 2025 and $3.7 million for Q1 2025.